CO5630027A2 - Agentes terapeuticos derivados de acido 3-fenilpropionico sustituido - Google Patents

Agentes terapeuticos derivados de acido 3-fenilpropionico sustituido

Info

Publication number
CO5630027A2
CO5630027A2 CO06001010A CO06001010A CO5630027A2 CO 5630027 A2 CO5630027 A2 CO 5630027A2 CO 06001010 A CO06001010 A CO 06001010A CO 06001010 A CO06001010 A CO 06001010A CO 5630027 A2 CO5630027 A2 CO 5630027A2
Authority
CO
Colombia
Prior art keywords
aryl
alkyl
alkylaryl
substituted
therapeutic agents
Prior art date
Application number
CO06001010A
Other languages
English (en)
Inventor
Lindstedt Eva-Lotte Alstermark
Boije Anna Maria Persdotter
Patrick Holm
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27636748&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5630027(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO5630027A2 publication Critical patent/CO5630027A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/56—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

1.- Un compuesto de fórmula I y sus sales farmacéuticamente aceptables, en la cual A se sitúa en la posición para y representa A1 ó A2 a continuaciónen donde R es hidrógeno;-ORa, en donde Ra representa hidrógeno, alquilo, arilo o alquilarilo;-NRaRb, en donde Ra y Rb son los mismos o diferentes y Ra es como se define anteriormente y Rb representa hidrógeno, alquilo, arilo, alquilarilo, ciano, -OH, -Oalquilo, -Oarilo, -Oalquilarilo, -CORc ó -SO2Rd, en donde Rc representa hidrógeno, alquilo, arilo o alquilarilo y Rd representa alquilo, arilo o alquilarilo;R1 es alquilo, arilo, alquenilo, alquinilo, ciano;-ORe, en donde Re es alquilo, acilo, arilo o alquilarilo;-O-[CH2]m -ORf, en donde Rf representa hidrógeno, alquilo, acilo, arilo o alquilarilo y m representa un entero 1-8;-OCONRaRc, en donde Ra y Rc son como se definen anteriormente;-SRd, en donde Rd es como se define anteriormente; ...
CO06001010A 2003-06-18 2006-01-05 Agentes terapeuticos derivados de acido 3-fenilpropionico sustituido CO5630027A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0314075.3A GB0314075D0 (en) 2003-06-18 2003-06-18 Therapeutic agents

Publications (1)

Publication Number Publication Date
CO5630027A2 true CO5630027A2 (es) 2006-04-28

Family

ID=27636748

Family Applications (1)

Application Number Title Priority Date Filing Date
CO06001010A CO5630027A2 (es) 2003-06-18 2006-01-05 Agentes terapeuticos derivados de acido 3-fenilpropionico sustituido

Country Status (21)

Country Link
US (1) US20060199857A1 (es)
EP (1) EP1638927A1 (es)
JP (1) JP2006527747A (es)
KR (1) KR20060023994A (es)
CN (1) CN1835917A (es)
AR (1) AR044828A1 (es)
AU (1) AU2004249474B2 (es)
BR (1) BRPI0411536A (es)
CA (1) CA2529297A1 (es)
CO (1) CO5630027A2 (es)
GB (1) GB0314075D0 (es)
IL (1) IL172632A0 (es)
IS (1) IS8227A (es)
MX (1) MXPA05013719A (es)
NO (1) NO20056005L (es)
RU (1) RU2005141062A (es)
SA (1) SA04250193B1 (es)
TW (1) TW200503999A (es)
UY (1) UY28370A1 (es)
WO (1) WO2004113282A1 (es)
ZA (1) ZA200510260B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
DK1517883T3 (da) 2002-06-20 2008-05-26 Astrazeneca Ab Ortho-substituerede benzoesyrederivater til behandling af insulinresistens
GB0314131D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0427524D0 (en) 2004-12-16 2005-01-19 Astrazeneca Ab Chemical process
KR101343443B1 (ko) * 2010-02-18 2013-12-19 재단법인 아산사회복지재단 콜키친 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조 방법 및 이를 포함하는 약학 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU170228B (es) * 1974-04-19 1977-04-28
SE9801990D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl propionic acid derivatives and analogs
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
MA26634A1 (fr) * 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
BR0210190A (pt) * 2001-06-07 2004-04-06 Lilly Co Eli Moduladores de receptores ativados de proliferador de peroxissomo
UA82835C2 (en) * 2001-12-03 2008-05-26 Reddys Lab Ltd Dr ?-aryl-?-oxysubstituted propionuc acid derivatives and pharmaceutical composition based thereon
SE0104333D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0314130D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314131D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314260D0 (en) * 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
CA2529297A1 (en) 2004-12-29
CN1835917A (zh) 2006-09-20
KR20060023994A (ko) 2006-03-15
AU2004249474B2 (en) 2008-05-15
IS8227A (is) 2006-01-10
JP2006527747A (ja) 2006-12-07
US20060199857A1 (en) 2006-09-07
BRPI0411536A (pt) 2006-08-01
TW200503999A (en) 2005-02-01
AR044828A1 (es) 2005-10-05
WO2004113282A1 (en) 2004-12-29
EP1638927A1 (en) 2006-03-29
GB0314075D0 (en) 2003-07-23
UY28370A1 (es) 2005-01-31
RU2005141062A (ru) 2006-07-10
ZA200510260B (en) 2007-01-31
MXPA05013719A (es) 2006-06-27
NO20056005L (no) 2006-02-24
SA04250193B1 (ar) 2007-08-13
IL172632A0 (en) 2006-04-10
AU2004249474A1 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
PE20040636A1 (es) Ester de 2'-c-metil-3'-o-l-valina de ribofuranosilcitidina
CO5150182A1 (es) Compuestos de triazol y su utilizacion
CY1113657T1 (el) Νεα παραγωγα βενζοφαινονης ή αλατα αυτων
ECSP088550A (es) Nuevos compuestos que son inhibidores de erk
DE60331187D1 (de) Kinaseinhibitoren
CO5630027A2 (es) Agentes terapeuticos derivados de acido 3-fenilpropionico sustituido
EA200600348A1 (ru) Новые соединения
DE60306398D1 (de) Gasgenerator
CY1105790T1 (el) Νεα μεθοδος για τη συνθεση πepιντοπριλ και των φαρμακευτικως αποδεκτων αλατων αυτου
AR039172A1 (es) Derivados de morfolina, antagonistas de ccr3.
UY27236A1 (es) Inhibidores de pcp basados en ácidos 3-heterociclilpropanohidroxámicos
DE60302554D1 (de) Gasgenerator
EA199901098A1 (ru) Новый способ
EA200600898A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
EA200501900A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
DE60225595D1 (de) Herstellung von siliziumverbrückten metallocenverbindungen
ECSP045291A (es) Preparación de ácido n1-(2'-piridil)-1,2-propanodiamino sulfámico y su uso en la síntesis de piperazinas biológicamente activas
EA200501925A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
CY1105699T1 (el) Νεες φαρμακευτικες ενωσεις με αλφα2υποδοχεα δραστηριοτητας
DE60323748D1 (de) 1,3-diaza-dibenzoazulene als inhibitoren der produfür deren herstellung
EA200600454A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
CY1105789T1 (el) Νεα μεθοδος για τη συνθεση πepιντοπριλ και των φαρμακευτικως αποδεκτων αλατων αυτου
ITMI992423A0 (it) Procedimento di sintesi diretta di fosfuro di indio
ES2286154T3 (es) Derivados de 5-amino-1-penten-3-ol sustituidos.
AR042740A1 (es) Diazepanes farmaceuticamente activos

Legal Events

Date Code Title Description
FC Application refused